ArticleFrontiers in oncology2025
Significant response to toripalimab plus axitinib for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromophobe renal cell carcinoma (chRCC) is a rare subtype of renal cell carcinoma (RCC). Sarcomatoid differentiation is considered a result of dedifferentiation of the primary tumor. The coexistence of both components (chromophobe and sarcomatoid) in a single renal tumor has been infrequently reported. Currently, only isolated cases of metastatic sarcomatoid chRCC treated with immune checkpoint inhibitors (ICIs) or targeted therapies have been documented. Here, we present the first case of metastatic sarcomatoid chRCC treated with toripalimab plus axitinib and provide a review of the relevant literature. During a routine physical examination, a 58-year-old male was found to have a left renal mass. Subsequent imaging with computed tomography urography (CTU) revealed a 3.4 × 2.3 cm hypovascular tumor located in the middle pole of the left kidney, which was clinically diagnosed as left renal cell carcinoma. The patient underwent robotic-assisted laparoscopic left radical nephrectomy, and histological analysis confirmed the presence of chromophobe renal cell carcinoma with sarcomatoid differentiation. Unfortunately, twelve months post-surgery, the patient was diagnosed with retroperitoneal lymph node metastasis. Treatment with toripalimab (3mg/kg, every 2weeks) plus axitinib (5 mg orally twice daily with a 12-hour interval) was initiated, and a significant response was observed after eight months. The treatment was well tolerated, with no significant adverse reactions, and the patient is currently continuing the treatment. Metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation is an extremely rare occurrence. The combination of toripalimab and axitinib may represent a promising treatment option for patients with chRCC and sarcomatoid differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.